The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Open accessAbstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with one agent showing benefit only among patients who had a baseline LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter. 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there were little more than 100 events in these studies combined.”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors showed significant reductions in cardiovascular outcomes.9,10”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
In the citing paper
“No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients [274].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18-25% has been observed.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men. 115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Results in studies with PCSK9 inhibitors that included post-ACS/very high-risk patients were promising 115,116 and definitive outcome studies are awaited.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Combination therapy using statin and ezetimibe prevents ASCVD incidence in patients with ACS. (Evidence level 1+, recommendation level: B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“The IMPROVE-IT study636) which enrolled ACS subjects (secondary prevention) with controlled LDL-C levels (50–100 mg/dL) under simvastatin treatment, revealed a significantly lower ASCVD incidence in the group for which ezetimibe was added on to simvastatin treatment.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“Regarding the LDL-C management target, the IMPROVE-IT636) study revealed that lowering the LDL-C level to 53.6 mg/dL using statin–ezetimibe combination therapy suppressed cardiovascular events by 6.4% more than the group that had their LDL-C level controlled at 69.5 mg/dL with statins only.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“(10,11).These agents dramatically reduce LDL-C levels over and above statin therapy, with favorable short-term outcomes data up to 18 months (11,12).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,004
Tan, J., Hu, M., Yang, Y., & Yang, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.798334 · Cited by 39
Laufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 39
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6666-1 · Cited by 36
A Genetic Approach to the Association Between PCSK9 and Sepsis
Feng, Q., Wei, W., Chaugai, S., Leon, B. G. C., Kawai, V. K., Leon, D. A. C., Jiang, L., Zhong, X. Y., Liu, G., Ihegword, A., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11130 · Cited by 35
Zhang, X., Geng, T., Li, N., Wu, L., Wang, Y., Zheng, D., Guo, B., & Wang, B. (2022) · Nutrients · doi:10.3390/nu15010069 · Cited by 35
Fowler, A., Rompay, K. K. A. V., Sampson, M. L., Leo, J., Watanabe, J., Usachenko, J. L., Immareddy, R., Lovato, D. M., Schiller, J. T., Remaley, A. T., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00743-6 · Cited by 39
Reality of a Vaccine in the Prevention and Treatment of Atherosclerosis
García‐González, V., Delgado‐Coello, B., Pérez‐Torres, A., & Mas‐Oliva, J. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.06.004 · Cited by 36
Navarese, E. P., Kołodziejczak, M. M., Dimitroulis, D., Wolff, G., Busch, H. L., Devito, F., Sionís, A., & Ciccone, M. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv045 · Cited by 36
Galema‐Boers, A. M. H., Lenzen, M. J., Sijbrands, E. J. G., & van Lennep, J. E. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.014 · Cited by 36
Toth, P. P., Jones, S. R., Monsalvo, M. L., Elliott‐Davey, M., López, J. A. G., & Banach, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014129 · Cited by 36
Recent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 36
Bruikman, C. S., Stoekenbroek, R. M., Hovingh, G. K., & Kastelein, J. J. P. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.010 · Cited by 38
Gencer, B., Koskinas, K. C., Räber, L., Karagiannis, A., Nanchen, D., Auer, R., Carballo, D., Carballo, S., Klingenberg, R., Heg, D., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006537 · Cited by 35
PCSK9 and the nervous system: a no-brainer?
Jaafar, A. K., Techer, R., Chemello, K., Lambert, G., & Bourane, S. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100426 · Cited by 35
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
Elshazly, M. B., Nicholls, S. J., Nissen, S. E., John, J. S., Martin, S. S., Jones, S. R., Quispe, R., Stegman, B., Kapadia, S. R., Tuzcu, E. M., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.021 · Cited by 35
Hu, D., Yang, Y., & Peng, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.064 · Cited by 35
Management of cardiovascular risk factors in patients with ANCA‐associated vasculitis
Bramlage, C. P., Kröplin, J., Wallbach, M., Minguet, J., Smith, K. H., Lüders, S., Schrader, J., Patschan, S., Groß, O., Deutsch, C., et al. (2017) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12709 · Cited by 35
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 35
Du, H., Li, X., Su, N., Li, L., Hao, X., Gao, H., Kwong, J. S.-W., Vandvik, P. O., Yang, X., Németh, I., et al. (2019) · Heart · doi:10.1136/heartjnl-2019-314763 · Cited by 36
PCSK9: A Potential Therapeutic Target for Sepsis
Yuan, Y., Wu, W., Sun, S., Zhang, Y., & Chen, Z. (2020) · Journal of Immunology Research · doi:10.1155/2020/2687692 · Cited by 35
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Kosmas, C. E., Skavdis, A., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288831 · Cited by 53
Korneva, V., Kuznetsova, T. Y., & Julius, U. (2021) · Biomedicines · doi:10.3390/biomedicines9091271 · Cited by 35
The Application of Genomics in Diabetes: Barriers to Discovery and Implementation
Floyd, J. S., & Psaty, B. M. (2016) · Diabetes Care · doi:10.2337/dc16-0738 · Cited by 35
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
Mátyás, C., Trojnár, E., Zhao, S., Arif, M., Mukhopadhyay, P., Kovács, A. D., Fábián, A., Tokodi, M., Bagyura, Z., Merkely, B. P., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.06.005 · Cited by 34
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Burnett, J. R., & Hooper, A. J. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2267972 · Cited by 36
Wang, Y., Pan, Y., Hou, M., Luo, R., He, J., Lin, F., Xia, X., Li, P., He, C., He, P., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115736 · Cited by 34
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 34
Self-citationPoirier, S., Hamouda, H. A., Villeneuve, L. R., Demers, A., & Mayer, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157230 · Cited by 35
PCSK9 and infection: A potentially useful or dangerous association?
Khademi, F., Momtazi‐Borojeni, A. A., Reiner, Ž., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26040 · Cited by 33
PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol
Wang, Y., & Liu, Z. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180423111442 · Cited by 34
From lipid locus to drug target through human genomics
van der Laan, S. W., Harshfield, E. L., Hemerich, D., Stacey, D., Wood, A., & Asselbergs, F. W. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy120 · Cited by 33
Zafrir, B., & Jubran, A. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12439 · Cited by 37
Schremmer, J., Busch, L., Baasen, S., Heinen, Y., Sansone, R., Heiß, C., Kelm, M., & Stern, M. E. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104513 · Cited by 34
Relation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Remembering Statins: Do Statins Have Adverse Cognitive Effects?
Bitzur, R. (2016) · Diabetes Care · doi:10.2337/dcs15-3022 · Cited by 33
Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options
Anagnostis, P. G., Karras, S. Ν., Lambrinoudaki, I. V., Stevenson, J. C., & Goulis, D. G. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12903 · Cited by 34
Susan-Resiga, D., Girard, E., Kiss, R. S., Essalmani, R., Hamelin, J., Asselin, M.-C., Awan, Z., Butkinaree, C., Fleury, A., Soldera, A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769430 · Cited by 35
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 34
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 34
Walsh, M. T., & Hussain, M. M. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1221883 · Cited by 32
Stam‐Slob, M. C., van der Graaf, Y., de Boer, A., Greving, J. P., & Visseren, F. L. J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.080 · Cited by 32
Health and societal implications of medical and technological advances
Dzau, V. J., & Balatbat, C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau4778 · Cited by 31
Fang, H., Chen, L., & Knight, J. C. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30134-1 · Cited by 32
Achimastos, A. D., Alexandrides, T., Alexopoulos, D. K., Athyros, V. G., Bargiota, Α., Bilianou, E., Chrysochoou, C., Drogari, E., Elisaf, M., Ganotakis, E., et al. (2016) · HORMONES · doi:10.1007/bf03401398 · Cited by 32
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 34
Self-citationRubba, P., Gentile, M., Marotta, G., Iannuzzi, A., Sodano, M., Simone, B. D., Jossa, F., Iannuzzo, G., Giacobbe, C., Taranto, M. D. D., et al. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317702040 · Cited by 32
Danese, M. D., Gleeson, M. L., Kutikova, L., Griffiths, R. I., Khunti, K. K., Seshasai, S. R. K., & Ray, K. K. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013851 · Cited by 31
A promising therapy for fatty liver disease: PCSK9 inhibitors
Han, L., Wu, L., Yin, Q., Li, L., Zheng, X., Du, S., Huang, X., Bai, L., Wang, Y., & Bian, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155505 · Cited by 31
Low High-Density Lipoprotein and Risk of Myocardial Infarction
Ramirez, A., & Hu, P. P. (2015) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s26624 · Cited by 31
Imaging Atherosclerotic Plaque Calcification: Translating Biology
Bailey, G., Meadows, J. L., & Morrison, A. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0601-6 · Cited by 31
Eisenga, M. F., Zelle, D. M., Sloan, J. H., Gaillard, S., Bakker, S. J. L., & Dullaart, R. P. F. (2017) · Diabetes Care · doi:10.2337/dc16-2258 · Cited by 31
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 31
Seidah, N. G., Chrétien, M., & Mbikay, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000484 · Cited by 31
Ying, H., Wang, J., Shen, Z., Wang, M., & Zhou, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07045-2 · Cited by 31
Jiang, Q., Qin, D., Yang, L., Lin, Y., Zhai, L., Zhang, Y., Yang, G., Wang, K., Tong, D., Li, X., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.011 · Cited by 33
Ortega-Rivera, O. A., Pokorski, J. K., & Steinmetz, N. F. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100014 · Cited by 31
Sanz, D. J., Raivola, J., Karvonen, H., Arjama, M., Barker, H. R., Murumägi, A., & Ungureanu, D. (2021) · Cancers · doi:10.3390/cancers13153727 · Cited by 30
Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction
Sun, H., Wang, J., Liu, S., Zhou, X., Dai, L. X., Chen, C., Xu, Q., Wen, X., Cheng, K., Sun, H., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00521 · Cited by 30
Cordero, A., Olmo, M. R. F., Quiroga, G. A. C., Romero‐Menor, C., Fácila, L., Seijas‐Amigo, J., Fornovi, A., Murillo, J. R., Rodríguez‐Mañero, M., Mora, M. C. B., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001205 · Cited by 33
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Cardiovascular pharmacogenomics: current status and future directions
Roden, D. M. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.78 · Cited by 32
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou, S., & Ray, K. K. (2017) · Heart · doi:10.1136/heartjnl-2016-310844 · Cited by 30
Galve, E., Cordero, A., Cequier, A. R., Ruiz, E., & González‐Juanatey, J. R. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.02.012 · Cited by 30
Plaque imaging to refine indications for emerging lipid-lowering drugs
Alkhalil, M., Chai, J. T., & Choudhury, R. P. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw034 · Cited by 30
Desai, N. R., Giugliano, R. P., Wasserman, S. M., Gibbs, J. P., Liu, T., Scott, R. C., & Sabatine, M. S. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5395 · Cited by 30
Self-citationHistory of lipidology and lipoprotein apheresis
Julius, U. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.034 · Cited by 30
Cordero, A., Rodríguez‐Mañero, M., Fácila, L., Fernández-Olmo, M. R., Gómez-Martínez, M. J., Valle, A., Castellano, J. M., Toro, M. M., Seijas‐Amigo, J., Vicedo-López, Á., et al. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00557-6 · Cited by 30
Taskinen, M., Björnson, E., Kahri, J., Söderlund, S., Matikainen, N., Porthan, K., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Fermanelli, V., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315446 · Cited by 31
PCSK 9 in diabetic kidney disease
Elewa, U., Fernández‐Fernández, B., Mahíllo, I., Martín-Cleary, C., Sanz, A. B., Sánchez-Niño, M. D., & Ortíz, A. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12661 · Cited by 30
Chackerian, B., & Remaley, A. T. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000312 · Cited by 29
Lipoprotein(a): new insights from modern genomics
Afshar, M. S., & Thanassoulis, G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000392 · Cited by 29
Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future
Delitala, A. P., Delitala, G., Sioni, P., & Fanciulli, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1330259 · Cited by 29
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 30
Zhang, Z., Wei, T., Zhao, B., Yin, Z. F., Shi, Q., Liu, P., Liu, L., Liu, L., Zhao, J., Mao, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-35773-x · Cited by 30
Environmentally responsive hydrogels for repair of cardiovascular tissue
Guan, S., Li, J., Zhang, K., & Li, J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09934-y · Cited by 29
Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
Guo, S., Xia, X.-D., Gu, H.-M., & Zhang, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_9 · Cited by 30
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 31
Exploiting nanoscale cooperativity for precision medicine
Wilhelm, J., Wang, Z., Sumer, B. D., & Gao, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.012 · Cited by 30
Estimation of the major cardiovascular events prevention with Inclisiran
Cordero, A., Santos‐Gallego, C. G., Fácila, L., Rodríguez‐Mañero, M., Bertomeu‐González, V., Castellano, J. M., Seijas‐Amigo, J., Núñez, J. E., Zuazola, P., González‐Juanatey, J. R., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.021 · Cited by 29
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 32
Hohenstein, B., Julius, U., Lansberg, P. J., Jaeger, B. R., Mellwig, K., Weiss, N., Graehlert, X., Roeder, I., & Ramlow, W. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.009 · Cited by 29
PCSK9 Inhibitors: A Technology Worth Paying For?
Weintraub, W. S., & Gidding, S. S. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0355-y · Cited by 29
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Stein, E. A., & Raal, F. J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0659-8 · Cited by 28
Self-citationNew developments in atherosclerosis: clinical potential of PCSK9 inhibition
Tavori, H., & Giunzioni, I. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s74692 · Cited by 29
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 28
Self-citationStein, E. A., & Raal, F. J. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6654-5 · Cited by 29
Self-citationElbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1206080 · Cited by 29
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 35
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
Safarova, M. S., Satterfield, B. A., Fan, X., Austin, E. E., Ye, Z., Bastarache, L. A., Zheng, N. S., Ritchie, M. D., Borthwick, K. M., Williams, M. S., et al. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0078-7 · Cited by 29
Farrah, T. E., Anand, A., Gallacher, P. J., Kimmitt, R. A., Carter, E., Dear, J. W., Mills, N. L., Webb, D. J., & Dhaun, N. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12919 · Cited by 28
Furtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 29
Self-citationNatarajan, P., & Kathiresan, S. (2016) · Cell · doi:10.1016/j.cell.2016.05.016 · Cited by 28
Hirai, K., Imamura, S., Hirai, A., Ookawara, S., & Morishita, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103338 · Cited by 28
Vicente-Valor, J., García‐González, X., Ibáñez-García, S., Durán-García, M. E., de Lorenzo‐Pinto, A., Rodríguez, C., Méndez, I., Percovich-Hualpa, J. C., Alonso, A. H., & Sanjurjo‐Sáez, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112519 · Cited by 29
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Momtazi‐Borojeni, A. A., Banach, M., Ruscica, M., & Sahebkar, A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2132229 · Cited by 28
Huo, Y., Chen, B., Lian, Q., Wang, S., Liu, L., Lu, D., Qu, Y., Zheng, G., Li, L., Ji, Y., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100907 · Cited by 28
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
Badia, L. A. D., Elshourbagy, N. A., & Mousa, S. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.011 · Cited by 29
Metadata
- Authors
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A.
- Affiliations
- University of Iowa (US)
- Harvard University (US)
- University of the Witwatersrand (ZA)
- University of Cape Town (ZA)
- Houston Methodist (US)
- Amgen (United States) (US)
- Jacksonville Center for Clinical Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1500-1509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238580056
- Semantic Scholar
- 3a2aa2d61647c779adc7c8fa42c75fb373940128
- Cited by
- 1,509
- References
- 26
- Citations by year
- 2026: 44 · 2025: 54 · 2024: 71 · 2023: 73 · 2022: 88 · 2021: 91 · 2020: 104 · 2019: 148 · 2018: 152 · 2017: 261 · 2016: 277 · 2015: 141
- FWCI
- 279.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- evolocumab, PCSK9 inhibitors, LDL cholesterol lowering, cardiovascular events, lipid-lowering therapy, drug efficacy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
